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Summary
Subsequent to demyelination in multiple sclerosis,
myelin repair occurs but, as lesions age, the ability to
remyelinate diminishes. Molecular pathways underlying
oligodendrocyte behaviour during CNS remyelination
remain to be elucidated. In this study, we report for
the ﬁrst time constitutive expression of the CXC/a
chemokine receptors, CXCR1, CXCR2 and CXCR3, on
oligodendrocytes in normal adult human CNS tissue, the
levels of which were upregulated in multiple sclerosis and
other neurological diseases (OND). In addition, both
immature (A2B5
+/O4
+) and more mature (CNPase
+)
human oligodendrocytes in vitro expressed the same
three receptors. The respective ligands to CXCR1,
CXCR2 and CXCR3 [i.e. CXCL8/IL-8, CXCL1/GRO-a
and CXCL10/IP-10), were absent in CNS tissue from
normals and subjects with OND, but were present
at high levels on hypertrophic (reactive) astrocytes at
the edge of active (but not silent) multiple sclerosis lesions.
Astrocytes in vitro could be induced to express chemo-
kines following stimulation with pro-inﬂammatory
cytokines. CXCL8 and CXCL1 production by human
astrocytes at both the RNA and protein levels could
be induced by interleukin (IL)-1b, while CXCL10 was
induced by both IL-1b and interferon-g. Since
these cytokines are integral to inﬂammatory events occur-
ring at the margins of active multiple sclerosis lesions,
their upregulation in these regions may underlie the
dynamics of chemokine expression observed herein.
The simultaneous expression of different CXC chemokine
receptors on oligodendrocytes, and their ligands on
astrocytes around multiple sclerosis lesions, may
bespeak novel functional roles for these immune system
molecules in the recruitment of oligodendrocytes and
remyelination.
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Introduction
Chemokines are small, 8–14 kDa, basic proteins classiﬁed
into four groups, CXC/a, CC/b,C / g and CX3C/d, based on
the N-terminal amino acid sequence. Through interactions
with seven transmembrane G protein-coupled receptors, che-
mokines have the ability to attract speciﬁc leukocyte cell
types and play a role in a number of inﬂammatory conditions,
including atherosclerosis, psoriasis and allergic responses
(Murdoch and Finn, 2000; Zlotnik and Yoshie, 2000). Studies
on multiple sclerosis and its animal model, experimental
autoimmune encephalomyelitis (EAE), have suggested that
chemokines may be involved in establishment of disease.
Th1-type effector cells expressing the chemokine receptors,
CCR5 and CXCR3, appear to be recruited into CNS paren-
chyma by the chemokines, CCL3/MIP-1a, CCL5/RANTES
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 and CXCL10/IP-10 (Karpus et al., 1995; Balashov et al.,
1999; Tran et al., 2000; Fife et al., 2001; Teleshova et al.,
2002), while CCL2/MCP-1, CCL3 and CCL5 are important
in recruitment of macrophages via interactions with CCR1,
CCR2 and CCR5 (Fife et al., 2000; Izikson et al., 2000;
Huang et al., 2001; Trebst et al., 2001). It has also become
evident that in addition to inﬁltrating cells of the immune
system, resident CNS cells can function as a source of che-
mokines. In this regard, astrocytes, microglia and endothelial
cells have been shown to produce a wide range of CXC and
CC chemokines (Cole et al., 1998; Janabi et al., 1999; Hua
and Lee, 2000; Shukaliak and Dorovini-Zis, 2000; Rezaie
et al., 2002; Salmaggi et al., 2002; Filipovic et al., 2003;
Meeuwsen et al., 2003; Omari et al., 2004). With regard to
chemokine receptors, such molecules have also been localized
on resident CNS cell types, speciﬁcally astrocytes, microglia
andneurons(Lavietal.,1997;Coughlanetal.,2000;Simpson
et al., 2000a,b; Goldberg et al., 2001; Biber et al., 2002;
Rezaie et al., 2002; Filipovic et al., 2003; Flynn et al., 2003).
Why resident CNS cells express chemokine receptors is
notentirelyunderstood.Chemokinereceptoractivationresults
in a number of downstream events including gene expression,
cell adhesion, cell polarization and chemotaxis. Data on
molecular pathways responsible for chemokine receptor sig-
nalling point to JAK/STAT proteins having an integral role
(Melladoetal.,2001).Intherat,oligodendrocytes,themyelin-
atingcellsoftheCNS,havebeenshowntoexpressatleasttwo
chemokinereceptors,CXCR1andCXCR2(NguyenandStan-
gel, 2001). CXCL1/GRO-a, one of the ligands to CXCR2
(others include CXCL2/GRO-b, CXCL3/GRO-g, CXCL5/
ENA78, CXCL7/NAP-2 and CXCL8/IL-8), has been shown
to play an important role in oligodendroglial development in
that these cells proliferate in vitro in response to CXCL1
(Robinson et al., 1998). Moreover, oligodendrocyte precursor
cell migration is halted in the presence of the same chemokine
in vivo (Tsai et al., 2002). CXCL8, the ligand to CXCR1
chemokine receptor, along with CXCL6/GCP-2, has not
beenshowntoaffectoligodendrocytes,butisknowntoinduce
proliferation of microvascular endothelium and tumour cells
(Heidemannetal.,2003;Mockenhauptetal.,2003;Zhuetal.,
2004). The chemokine, CXCL10, which shares the receptor
CXCR3 with CXCL9/MIG and CXCL11/I-TAC, has been
widely implicated to play an important role in the recruitment
of leukocytes into the CNS (Balashov et al., 1999; Fife et al.,
2001; Sorensen et al., 2002). Flynn et al. (2003) have also
reported on the ability of CXCL10 to induce proliferation of
human adult astrocytes in vitro. To date, there have been no
studies on the expression and role of chemokine receptors on
human oligodendrocytes.
Oligodendrocytes are a primary target in multiple sclerosis
and are severely depleted during the course of the disease
(Raine, 1997). However, mechanisms underlying the demise
of oligodendrocytes remain in question (D’Souza et al., 1996;
Bonetti and Raine, 1997; Lucchinetti et al., 2000; Barnett and
Prineas, 2004). Interestingly, around some active lesions,
oligodendrocytes are not only preserved, but may exist in
increased numbers, indicating oligodendroglial hyperplasia
(Raine et al., 1981; Prineas et al., 1989). It remains to be
determined whether oligodendrocyte precursor cells (OPCs),
or surviving cells, may be the source of new oligodendro-
cytes. Despite the presence of OPCs (Scolding et al., 1998;
Chang et al., 2000; Maeda et al., 2001; Wolswijk, 2002),
remyelination in multiple sclerosis is usually limited in extent
(Prineas et al., 1993; Raine and Wu, 1993; Franklin, 2002).
Related to this is evidence showing that oligodendrocyte
maturation may be blocked via inhibitory signals (Wang
et al., 1998; John et al., 2002). Other pathways inﬂuencing
oligodendrocyte behaviour during the course of multiple
sclerosis probably exist but remain to be elucidated. Perhaps
relevant to this is the presence of receptors normally associ-
ated with the immune system on human oligodendrocytes,
suggesting that this cell type may respond to other inﬂam-
matory signals (D’Souza et al., 1996; Bonetti and Raine,
1997; Cannella and Raine, 2004).
In view of current interest in chemokines and other factors
that may inﬂuence oligodendroglial recruitment in multiple
sclerosis, we have investigated expression of CXC chemo-
kine receptors and a subset of their ligands during the course
of the disease. Here, we demonstrate expression of the three
receptors, CXCR1, CXCR2 and CXCR3, on oligodendro-
cytes in CNS samples from normal human, multiple sclerosis
and other neurological disease (OND) cases, and on fetal
human oligodendrocytes in vitro. In contrast, the respective
ligands, CXCL8, CXCL1 and CXCL10, were not found in
normal and OND samples, but were detected at high levels
on hypertrophic astrocytes around active multiple sclerosis
lesions. Interestingly, human astrocytes in vitro could be
induced to produce high levels of these CXC chemokines
after stimulation with proinﬂammatory cytokines, the latter
known to be important in multiple sclerosis (Benvenuto et al.,
1992; Link et al., 1994; Cannella and Raine, 1995). Taken in
concert, our results suggest that oligodendrocyte behaviour
during the course of multiple sclerosis may be inﬂuenced by
astrocyte-derived CXC chemokines.
Material and methods
Human tissue samples
Cryostat sections were prepared from seven cases of multiple scler-
osis, three primary progressive and four secondary progressive, con-
taining chronic active and silent lesions. Control sections came from
cerebral white matter from OND cases [olivopontocerebellar degen-
eration (OPCD), amyotrophic lateral sclerosis (ALS) and stroke], in
additiontotissuefromthreeneurologicallynormalsubjects(Table1).
For work in vitro, human fetal glial cells were isolated from fore-
brain and spinal cord tissue, obtained from the Einstein Human Fetal
TissueRepository(NewYork,NY).Useofhumantissuewasconduc-
ted in accordance with approved Internal Review Board protocols.
Immunohistochemistry
Frozen sections (10 mm) ﬁxed in acetone were quenched for endo-
genous peroxidase activity and blocked for 1 h with 10% normal
1004 K. M. Omari et al.
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 goat or rabbit sera. Sections were then incubated with primary
antibodies against CXCR1 (IgG2a; 1:100), CXCR2 (IgG2a;
1:50) and CXCR3 (IgG1; 1:100) (R&D Systems, Minneapolis,
MN); or their ligands CXCL8, CXCL1 and CXCL10 (goat poly-
clonals; 1:10; R&D Systems), diluted in 2% normal goat or rabbit
serum for 36 h at 4 C. Immunoreacted sections were then developed
by incubation with secondary biotinylated antibodies, followed
by the Vectastain avidin–biotin complex (ABC) solution (Vector
Laboratories, Burlingame, CA), and 3,30-diaminobenzidine (DAB)
solution (KPL, Gaithersburg, MD). Two-colour immunohistochem-
istry was performed by re-incubating CXCL1-labelled slides with
primary anti-CXCR2 antibody, followed by biotinylated anti-mouse
IgG2a antibody (SouthernBiotech, Birmingham, AL), ABC solution
and then Vector VIP peroxidase chromogen (Vector). To prevent
cross-reactivity, slides were treated with a biotin/avidin blocking
reagent (Vector) prior to incubation with the second primary
antibody. As negative controls, sections were incubated with
isotype-matched irrelevant antibodies (monoclonal IgG2a and
IgG1; BD Biosciences, San Diego, CA), at the same concentration
as the primary antibody, or with carrier buffer alone. To rule out
non-speciﬁc staining further, the anti-CXCL1 polyclonal
antibody was adsorbed using soluble human recombinant CXCL1
(100 ng/ml; R&D Systems) for 1 h at room temperature, then
applied to multiple sclerosis tissue sections and developed as
described above.
For immunoﬂuorescent staining, following ﬁxation, sections were
incubated with 0.1% glycine for 20 min to quench autoﬂuorescence,
and were then blocked with normal goat or rabbit serum. Oligo-
dendroglialidentitywasconﬁrmedwithantibodiesto20,30-cyclicnuc-
leotide30-phosphodiesterase(CNPase;IgG1;1:300;Sigma,StLouis,
MO), and astroglial identity with S-100 (IgG1; 1:200; Sigma) and
glial ﬁbrillary acidic protein (GFAP; IgG1; 1:200; Sigma). These
phenotypic markers were used in combination with CXCR and
CXCL antibodies for purposes of double labelling (Table 2).
Slides were then incubated with a combination of secondary
antibodies: biotinylated goat anti-mouse IgG2a (1:100)/Texas red-
conjugated goat anti-mouse IgG1 (1:100; SouthernBiotech) or biot-
inylated rabbit anti-goat IgG (1:300; Vector)/Texas red-conjugated
goatanti-mouseIgG1(1:100),followedby5mg/mlstreptavidincon-
jugated to ﬂuorescein isothiocyante (FITC; Jackson Immuno-
Research, West Grove, PA).
Isolation and culture of human glial cells
Primary cultures of human oligodendrocytes were established from
18–22 week gestation fetal spinal cords as described previously
(Wilson et al., 2003). After enzymatic digestion and overnight
incubation, the oligodendroglial-enriched cell suspension was gently
aspirated, centrifuged and the oligodendrocytes resuspended in
N2B3 medium, i.e. Dulbeco’s modiﬁed Eagles medium (Sigma)
supplemented with 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 0.25 mg/ml amphotericin B (all from Gibco
BRL, Carlsbad, CA), 0.5 mg/ml insulin, 0.1 mg/ml holo-transferrin,
16 mg/ml putrescine, 0.4 mg/ml thyroxine (T4), 0.3 mg/ml tri-
iodothyronine (T3), 0.06 mg/ml progesterone, 0.04 mg/ml sodium
selenite (all from from Sigma) and 0.1 mg/ml bovine serum albumin
path-o-cyte 4 (ICN Biomedicals, Aurora, OH). Cells were plated
onto glass coverslips coated with 5 mg/ml poly-L-lysine (Sigma), at a
density of 1–3 3 10
4 cells per coverslip. Oligodendrocyte cultures
were maintained in N2B3 medium alone, or supplemented with
10 ng/ml platelet-derived growth factor (PDGF)-AA (Sigma), and
medium was replenished every other day for up to 6 days.
Astrocytes were isolated from human fetal forebrain and spinal
cord, using methods similar to those described by Lee et al. (1992).
After removing the oligodendroglial-enriched supernatant ﬂuid,
cells attached to the 25 cm
2 tissue culture ﬂask were re-incubated
Table 1 Summary of cases utilized for immunohistochemistry
Case no. Diagnosis Disease duration
(years)
Sex/age
(years)
Cause of death Post-mortem
interval (h)
1 PPMS 11 F/31 Respiratory failure 3
2 PPMS 17 F/37 Respiratory failure 6
3 PPMS 4 F/32 Bronchopneumonia 12
4 SPMS 9 F/45 Cardiac arrest 11
5 SPMS 10 F/38 Bronchopneumonia 8
6 SPMS 21 F/56 Cardiac arrest 2
7 SPMS 15 M/46 Cardiac arrest 8
8 OPCD 4 M/31 Bronchopneumonia 4
9 ALS 5 F/49 Bronchopneumonia 8
10 Stroke 12 h F/80 Stroke 5
11 Normal NA M/19 Cardiac arrest/obesity 9
12 Normal NA M/40 Adult respiratory distress 8.5
13 Normal NA F/80 Metastatic cancer 6
PPMS = primary progressive multiple sclerosis; SPMS = secondary progressive multiple sclerosis;
OPCD = olivopontocerebellar degeneration; ALS = amyotrophic lateral sclerosis; NA = not applicable.
Table 2 Antibody combinations used for
immunoﬂuorescence staining
CXC receptor/ligand Phenotypic maker
A2B5 O4 CNPase S-100
CXCR1 C C C, T –
CXCR2 C C C, T –
CXCR3 C C –
  –
CXCL1 – – – T
CXCL8 – – – T
CXCL10 – – – T
C=culturedcells;T=tissueslides;– = nottested.
 Combination
not tested since both CXCR3 and CNPase antibodies are
mouse IgG1.
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 in RPMI-1640 medium supplemented with 10% fetal calf
serum (both from Gibco), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 0.25 m/ml amphotericin B for 10–14
days without agitation. To obtain a pure population of astrocytes,
microglia were removed by shaking and the remaining astrocytes
were passaged at least twice before being plated onto 100 mm cell
culture dishes or 24-well cell culture plates (Corning Incorporated,
Corning, NY). Astrocytes were maintained in serum-supplemented
RPMI in a 37 C/7% CO2 incubator, with medium change twice a
week. Upon reaching conﬂuence, cells were treated for 6–48 h with
interleukin (IL)-1b, interferon (IFN)-g (both from PeproTech,
Rocky Hill, NJ) or bacterial lipopolysaccharide (LPS, Sigma), at
a ﬁnal concentration of 0.1–100 ng/ml. After stimulation, supernat-
ant ﬂuid was collected and stored at  20 C.
Immunocytochemistry
Oligodendrocytes maintained in culture were processed for
immunocytochemistry as previously described (Robinson et al.,
1998; Wilson et al., 2003). Cells ﬁxed with 2% paraformaldehyde
(Sigma) were incubated with primary antibodies against CXCR1
(IgG2a; 1:100), CXCR2 (IgG2a; 1:50) or CXCR3 (IgG1;
1:100), in combination with either A2B5 (IgM; 1:200; Chemicon,
Temecula, CA) or CNPase (IgG1; 1:100), diluted in 2% normal
goat serum for 1 h at 37 C. After washing, oligodendrocytes were
incubated for 1 h at 37 C with biotinylated goat anti-mouse IgG2a
(1:100), or biotinylated goat anti-mouse IgG1 (1:100; Southern-
Biotech), plus Texas red-conjugated goat anti-mouse IgM
(1:100; Vector) or Texas red-conjugated goat anti-mouse IgG1
(1:200). Live cell staining was conducted to co-localize CXC
receptors with the early oligodendrocyte marker, O4 (IgM;
1:200; Chemicon). Cells were incubated with chemokine receptor
antibodies together with the marker O4, then incubated with bio-
tinylated goat anti-mouse IgG2a/IgG1 plus Texas red-conjugated
goat anti-mouse IgM, prior to ﬁxation. Oligodendrocytes were
then incubated with ﬂuorescein-conjugated streptavidin (5 mg/ml)
for 45 min at room temperature. Table 2 summarizes the combina-
tions of antibodies used for immunoﬂuorescent staining. As a con-
trol, oligodendrocytes were incubated with isotype-matched
irrelevant antibody (monoclonal IgG2a and IgG1), at the same con-
centration as the primary antibody.
Enzyme-linked immunosorbent assays (ELISA)
Production of CXC chemokines by astrocytes following treatment
with cytokines or LPS was determined using Quantikine
1 ELISA
kits speciﬁc for CXCL8, CXCL1 and CXCL10 according to the
manufacturer’s instructions (R&D Systems). Brieﬂy, cell culture
supernatant ﬂuid and standards were added to wells pre-coated
with capture antibodies speciﬁc for each chemokine, and incubated
for1.5–2 h at room temperature. Wells were then incubated for 1–2 h
with horseradish peroxidase (HRP)-conjugated antibodies at room
temperature for CXCL8 and CXCL10, or 4 C for CXCL1, followed
by addition of substrate (tetramethylbenzidine; TMB). Colour devel-
opment was allowed to occur for 30 min at room temperature before
introduction of 1 M sulfuric acid. Absorbance was measured at 450
nm with correction at 540 nm on a SpectraMax Plus microplate
spectrophotometer (Molecular Devices Corp., Sunnyvale, CA). Sub-
sequently, amounts of chemokines in cell culture supernatant ﬂuid
were calculated using SoftMax Pro v2.1.1 (Molecular Devices
Corp.). Baseline chemokine production was determined by analys-
ing supernatant ﬂuid from astrocytes maintained in serum-
supplemented RPMI in the absence of cytokines or LPS. Chemokine
production was tested in duplicate wells and repeated using two
different astrocyte cultures.
Quantitative polymerase chain reaction (PCR)
With a previously described protocol (Yuen et al., 2002a), each
transcript in each sample was assayed ﬁve times and the median
detection threshold (CT) values were used to calculate the Fp values
(fold-change ratios between experimental and control samples for
each gene), used in the analysis. Amplicon size and reaction spe-
ciﬁcity were conﬁrmed by agarose gel electrophoresis. Data validity
by modelling of reaction efﬁciency and analysis of measurement
precision have been described elsewhere (Yuen et al., 2002b).
Primers used for the detection of CXC chemokines were as follows:
CXCL8F 50-GGC CAA GAG AAT ATC CGA AC-30, CXCL8R 50-
AGG CAC AGT GGA ACA AGG AC-30; CXCL1F 50-TGA GAT
CAT TGT GAA GGC AG-30, CXCL1R 50-GAG AAA TGT TGA
CCA CAC AC-30; CXCL10F 50-TCC CAT CAC TTC CCT
ACA TG-30, and CXCL10R 50-TGA AGC AGG GTC AGA
ACA TC-30.
Data acquisition and analysis
Digital images of tissue sections and cultured cells were acquired
on a Zeiss Axioskop epiﬂuorescent microscope (Carl Zeiss,
Thornwood, NY) or a BioRad Radiance 2000 Scanning Laser Con-
focal microscope (Bio-Rad, Hercules, CA). All data were subjected
to analysis of variance (ANOVA) to determine differences between
treatment groups. Where differences were found, the Student’s t test
was applied to analyse individual differences against control groups.
The Mann–Whitney rank sum test was applied to data that were
not normally distributed. Data were analysed using SigmaStat v2.03
and graphs were generated on SigmaPlot 2001 (SPSS Science,
Chicago, IL).
Results
Human oligodendrocytes express CXC
chemokine receptors
Immunostaining of normal white matter showed low level
constitutive expression of CXCR1 and CXCR2 on small
rounded cells with the size and distribution of interfascicular
oligodendrocytes (Fig. 1A and E). In multiple sclerosis sec-
tions, higher level immunoreactivity for CXCR1 (Fig. 1B and
C) and CXCR2 (Fig. 1F and G) was detected on interfascicu-
lar oligodendrocytes around active and silent lesions. Simil-
arly, oligodendrocytes in all sections from OND cases
displayed an increase in reactivity for CXCR1 and CXCR2
over normal levels (Fig. 1D and H). Low magniﬁcation across
active multiple sclerosis lesion margins revealed increased
immunoreactivity for CXCR2, which was readily observed in
areas displaying an increase in oligodendrocyte numbers
(oligodendrocyte hyperplasia), regions ﬂanked by normal-
appearing white matter (NAWM) and demyelinated plaque
(Fig. 1M). Immunoﬂuorescent staining was performed to
1006 K. M. Omari et al.
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 Fig. 1 Human oligodendrocytes express CXCR1 (A–D), CXCR2 (E–H) and CXCR3 (I–L) chemokine receptors in situ. Note the weak
constitutive expression of CXCR1 (A), CXCR2 (E) and CXCR3 (I) on small rounded cells, typical of interfascicular oligodendrocytes, in
normal human white matter. In contrast, upregulated CXCR1 (B–D) and CXCR2 (F–H) expression was observed on oligodendrocytes
in frozen sections from multiple sclerosis and OND, while CXCR3 (J–L) staining intensity was consistently low in all cases tested. On
occasion, astrocytes were strongly positive for CXCR3 in multiple sclerosis tissue (K), but not in normals or OND. In M, CXCR2
+
oligodendrocytes are seen between the demyelinated plaque (
 ) on the right and the normal-appearing white matter (NAWM) to the left, a
prominent zone of oligodendrocyte hyperplasia. In N and O, the oligodendroglial nature of cells positive for CXC receptors was conﬁrmed
by immunoﬂuorescence and phenotypic staining. In multiple sclerosis, the oligodendrocyte marker, CNPase, co-localized with cells bearing
CXCR1 (N) and CXCR2 (O) chemokine receptors. The merged images on the right conﬁrm double labelling. Scale bars = 7.5 mm( A–L,
N and O); 94 mm( M).
CXC receptors on human oligodendrocytes 1007
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 conﬁrm identiﬁcation of the cells expressing CXC chemokine
receptors further. Sections were stained for CXCR1 and
CXCR2 in combination with the oligodendrocyte marker,
CNPase. Similar to immunoperoxidase staining, confocal
microscopy demonstrated that interfascicular oligodendro-
cytes expressing CXCR1 or CXCR2 were also positive for
CNPase (Fig. 1N and O). The results of the immunohisto-
chemistry analysis are summarized in Table 3.
In contrast to CXCR1 and CXCR2, CXCR3 was present at
low levels on oligodendrocytes in both normal and disease
groups (Fig. 1I–L). Moreover, in multiple sclerosis tissue,
astrocytes displayed more pronounced staining for CXCR3
compared with astrocytes in OND and normal controls.
Recognizing that astrocytes and microglia in vitro have
been reported to express CXC chemokine receptors (Biber
et al., 2002; Rezaie et al., 2002; Flynn et al., 2003), we paid
particular attention to these cells. In multiple sclerosis sam-
ples only, hypertrophic astrocytes were occasionally weakly
reactive for CXCR1 and CXCR2, and neurons in grey matter
also displayed immunoreactivity (data not shown). We can-
not speculate on the expression of CXCR1 or CXCR2 on
microglia as the antibodies applied were of the IgG2a isotype,
reagents well known for binding non-speciﬁcally to Fc
receptors (Ulvestad et al., 1994). This was conﬁrmed when
tissue sections from both normal and diseased CNS tissue
were incubated with an IgG2a isotype-matched irrelevant
antibody, which gave positive staining for microglia. Substi-
tution of the anti-CXCR3 antibody with an IgG1 irrelevant
antibody showed lack of non-speciﬁc binding by the primary
antibody.
In addition to expression in situ, CXC chemokine receptors
were examined in vitro in cultures of human oligodendro-
cytes. Immature A2B5
+ oligodendrocytes expressed
CXCR1, CXCR2 and CXCR3 (Fig. 2A–C). Similarly,
O4
+ oligodendrocytes also stained positively for CXCR1
and CXCR2 (Fig. 2D and E). Oligodendrocytes expressing
O4 displayed less elaborate staining for CXCR3 (data not
shown), an expected ﬁnding in view of the low expression
of CXCR3 detected in situ. Developmentally more mature
oligodendrocytes, being highly branched and positive for
CNPase, displayed CXCR1 and CXCR2 (Fig. 2E and G).
This ﬁnding was in agreement with the immunohistochem-
istry of CNS tissue, which showed CXCR1- and CXCR2-
bearing oligodendrocytes double labelled with CNPase. All
three CXC chemokine receptors appeared to be present
on the surface of oligodendrocytes, especially in cultures
double labelled with the oligodendrocyte marker, O4,
where the antibodies were applied on unﬁxed cells. In
instances where cells were ﬁxed prior to double labelling
with antibodies to chemokine receptors and oligodendroglial
markers (A2B5 and CNPase), intracellular staining was
observed in addition to surface expression. To rule out non-
speciﬁc staining by CXCR-speciﬁc antibodies, oligodendro-
cytes were incubated with isotype-matched irrelevant control
antibodies and these yielded negative results (Fig. 2H). Thus,
human oligodendrocytes consistently showed chemokine
receptor expression, the levels of some of which were elev-
ated in multiple sclerosis and OND samples.
CXC ligands are upregulated on hypertrophic
astrocytes in active multiple sclerosis
Immunoperoxidase staining for the respective ligands for
CXCR1, CXCR2 and CXCR3 chemokine receptors, i.e.
CXCL8/IL-8, CXCL1/GRO-a and CXCL10/IP-10, displayed
labelling of astrocytes only. In particular, hypertrophic astro-
cytes in active multiple sclerosis lesions reacted strongly for
CXCL8 and CXCL1 (Fig. 3A and B). Moreover, at the edge
of some lesions, CXCL1-expressing astrocytes occurred
adjacent to oligodendroglial cells positive for CXCR2
(Fig. 3C). In contrast to active lesions, in silent multiple
sclerosis, astrocytes displayed diminished expression of
CXCL8 and CXCL1 (Fig. 3D and E). To check for speciﬁcity
of the staining pattern, we found that adsorption of the anti-
CXCL1 polyclonal antibody with recombinant human
CXCL1 protein prior to incubation abolished immunoreact-
ivity (Fig. 3F). Also, minimal DAB product was observed on
tissue sections where the primary antibody was omitted (data
not shown). In the case of CXCL10, strong staining was
detected on hypertrophic astrocytes in active multiple scler-
osis (Fig. 3G), and reduced expression was present on astro-
cytes in silent multiple sclerosis lesions. To conﬁrm the
astroglial phenotype of cells expressing CXCL8 and
CXCL1, multiple sclerosis tissue was double stained with
an antibody against a marker for astrocytes, S-100 (Fig. 3H
and I). Again, only reactive astrocytes around active multiple
sclerosis lesions expressed high levels of chemokines.
Table 3 CXC receptor and ligand expression in CNS tissue
CNS tissue CXCR1 CXCL8 CXCR2 CXCL1 CXCR3 CXCL10
Active multiple sclerosis A+/–; OL+ A+/++ A+/–; OL+/++ A++ A++; OL+/– A+/++
Silent multiple sclerosis A+/–; OL+ A+/– A+/–; OL+ A+/– A++; OL+/– A+
OND
  OL+ ND OL+ ND A+; OL+/– ND
Normal OL+/– ND OL+ ND A+; OL+/– ND
OND = other neurological disease; OL = oligodendrocyte; A = astrocyte. Scoring scale: +/– = weak; + = moderate; ++ = strong; +++ =
very strong; ND = none detected.
 OPCD, ALS and stroke.
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 A key ﬁnding was the expression pattern of CXC ligands in
active multiple sclerosis lesions. Hypertrophic astrocytes at
the lesion edge (Fig. 4A) labelled positively with both
CXCL8 (Fig. 4B) and CXCL1 (Fig. 4C). Blood vessel ele-
ments also appeared to stain with antibodies against CXCL8
and CXCL1. However, no staining for either chemokine was
detectedinadjacentregionsofNAWM.Equallysigniﬁcantwas
theobservationthatinONDandnormalcontrolwhitematter,no
reaction for any of the above chemokines was observed on
astrocytes. In adjacent sections, the same cell type stained
intensely for the astrocytic marker GFAP, proving that astro-
cyteswerepresentinthetissue(Fig.3D–I).Therefore, expres-
sion of CXC ligands was limited to hypertrophic astrocytes in
active stages of disease and was absent in control tissue.
IL-1b and IFN-g regulate CXC chemokine
synthesis by astrocytes in vitro
To date, the factors involved in the production of CXC che-
mokines by glial cells have not been entirely deﬁned. Several
studies have shown that astrocytes can be stimulated to pro-
duce CXC chemokines (Cole et al., 1998; Janabi et al., 1999;
Salmaggi et al., 2002; Meeuwsen et al., 2003). To elucidate
further the mechanisms by which astrocytes may be induced
to produce CXC chemokines, we measured secretion of
CXCL8, CXCL1 and CXCL10 by sandwich ELISAs follow-
ing incubation of human astrocytes in vitro with the proin-
ﬂammatory cytokines, IL-1b and IFN-g, as well as LPS.
Astrocytes maintained in the absence of cytokine stimulation
produced minimal amounts of CXCL8 (144–450 pg/ml),
CXCL1 (8.5–81pg/ml)or CXCL10 (306–1098 pg/ml). Treat-
ment of astrocytes with IL-1b resulted in dramatic upregu-
lation of CXCL8 (54- to 882-fold) and CXCL1 (55- to
1328-fold). At the range tested, cytokine concentration had
little effect on chemokine level. However, the increase in
CXCL8 and CXCL1 production was time dependent, and
the highest levels were detected in supernatant ﬂuid from
astrocytes stimulated for 24–48 h (Fig. 5A–D). Stimulation
with LPS resulted in a minor upregulation in CXCL8 and
CXCL1 secretion compared with IL-1b (63- and 55-fold
average increase, respectively), while IFN-g had no effect
(Fig. 5A and C). Unlike CXCL8 and CXCL1, CXCL10 secre-
tion appeared to be consistently upregulated following
incubation with IFN-g (2- to 13-fold increase; Fig. 5E and
F). Peak CXCL10 levels were present in supernatant ﬂuid
from astrocytes treated for 24 h with 10–100 ng/ml IFN-g.I n
most instances, there was minimal CXCL10 production (<5-
fold increase) by spinal cord-derived astrocytes treated with
IL-1b (Fig. 5E). In experiments looking at the effects of time
on CXC chemokine production, one set of cultures used was
derived from forebrains. In the case of CXCL10, we observed
a large increase in chemokine secretion by forebrain-derived
astrocytes in response to 10 ng/ml IL-1b. When combined
with spinal cord-derived astrocytes, this resulted in an overall
large amount of CXCL10 production (15-fold average
Fig. 2 Human oligodendrocytes display surface expression of
CXC chemokine receptors in vitro.I nA–C, immature A2B5
+
oligodendrocytes co-express CXCR1 (A), CXCR2 (B) and CXCR3
(C) receptors. Similarly, in D and E, cells positive for the early
oligodendroglial marker, O4, also labelled with CXCR1 (D) and
CXCR2 (E). F and G show mature, highly branched
oligodendrocytes bearing the marker CNPase, double staining with
antibodies against CXCR1 (F) and CXCR2 (G). Non-speciﬁc
binding was assessed by incubating cells with isotype-matched
irrelevant antibodies, resulting in negative staining (H). Scale
bars = 15 mm( A–H).
CXC receptors on human oligodendrocytes 1009
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 increase; Fig. 5F). A possible explanation for this observation
could be the recent ﬁnding that IL-1 induces the interferon
regulatory factor-3 in human forebrain astrocytes, and thus
activates genes typically induced by IFN-g (Rivieccio et al.,
2004). Our results might suggest differences between spinal
cord- and forebrain-derived astrocytes in response to IL-1b
stimulation. Astrocytes incubated with LPS produced
substantially lower amounts of CXCL10 (1.0-fold average
increase; Fig. 5E).
Induction of CXC chemokines by astrocytes was analysed
further at the RNA level from forebrain-derived cultures. In
agreement with the results obtained by sandwich ELISAs,
quantitative PCR experiments showed that stimulation with
10 ng/ml IL-1b resulted in upregulation of CXCL8 and
CXCL1 RNA over control levels. Maximal amounts of
CXCL8 and CXCL1 RNA were detected after 6–24 h stimu-
lation, which preceded the highest level of chemokine protein
present in supernatant ﬂuid collected after 48 h treatment with
IL-1b (Fig. 6A and B). Similarly, stimulation with IL-1b
resulted in a rapid induction of CXCL10 RNA in astrocytes
after 6 h, which diminished over time. In contrast, astrocytes
treated with 10 ng/ml IFN-g showed sustained upregulation of
CXCL10 RNAover the48 htestperiod(Fig. 6C). Thus, astro-
cyte production of CXCL8, CXCL1 and CXCL10 in vitro
appearedtobeunderthecontrolofproinﬂammatorycytokines.
Discussion
In the present study, we demonstrate for the ﬁrst time on
human oligodendrocytes the expression of CXCR1,
CXCR2 and CXCR3, chemokine receptors commonly
found on granulocytes, monocytes, mast cells and lympho-
cytes (Murdoch and Finn, 2000; Murphy et al., 2000). While
human oligodendrocytes constitutively expressed all three
chemokine receptors, higher levels of CXCR1 and CXCR2
were seen in multiple sclerosis, and to a lesser extent in OND.
On the other hand, CXCR3 reactivity was low in all condi-
tions examined. Parallel experiments on human oligodendro-
cytes in vitro revealed that both immature (A2B5
+/O4
+)
and more mature (CNPase
+) oligodendrocytes displayed
the same three chemokine receptors. In view of the known
hyperplasia of oligodendrocytes around active multiple
sclerosis lesions (Raine et al., 1981; Prineas et al., 1989;
also see Fig. 1M), we propose that the above expression
pattern may be signiﬁcant to oligodendrocyte behaviour dur-
ing the course of disease. However, whether CXC chemokine
receptor signalling leads to the proliferation of human oligo-
dendrocytes or prevents their migration (both of which
would culminate in increased cell numbers) remains to be
determined.
Interestingly, the ligands to CXCR1, CXCR2 and CXCR3
(CXCL8, CXCL1 and CXCL10, respectively) were only
Fig. 3 Frozen sections displaying expression of CXC ligands on hypertrophic astrocytes in multiple sclerosis lesions. Immunoperoxidase
staining revealed high levels of CXCL8 (A) and CXCL1 (B) on hypertrophic astrocytes in active multiple sclerosis lesions. In C,
CXCL1-(brown) expressing astrocytes were found in close proximity to CXCR2- (purple) positive oligodendrocytes at the edge of an active
lesion. In contrast, limited staining of CXCL8 and CXCL1 was observed on astrocytes in silent multiple sclerosis (D and E). Lack of
non-speciﬁc staining is demonstrated by adsorption of the CXCL1 antibody with recombinant human CXCL1 (F). Reactive astrocytes in
active multiple sclerosis cases were also strongly positive for CXCL10 (G). The astroglial nature of cells producing CXCL8 (H) and
CXCL1 (I) in active multiple sclerosis lesions was conﬁrmed by double immunoﬂuorescence staining with S-100, a marker for reactive
astrocytes. Scale bars = 7.5 mm( A, B, D–I); 15 mm( C).
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 presentonhypertrophicastrocytesaroundactivemultiplescler-
osis lesions, being totally absent in normal and OND samples.
Double staining revealed the presence of chemokine-positive
(CXCL1) reactive astrocytes associated with chemokine
receptor-expressing (CXCR2) oligodendrocytes at the active
lesion margin, implying a functional relationship. Since few
reports exist to date on CXC chemokines and human astro-
cytes (Cole et al., 1998; Janabi et al., 1999; Simpson et al.,
Fig. 4 CXC ligands are selectively expressed by hypertrophic astrocytes in active multiple sclerosis lesions. Hypertrophic astrocytes present
at the edge of active multiple sclerosis lesions, demonstrated in sections stained by the Luxol fast blue method (A), label positively for
CXCL8 (B) and CXCL1 (C). CXC ligands are speciﬁcally expressed in regions near the lesion, while there is a lack of CXCL8 and CXCL1
staining in areas of NAWM. In contrast, other than staining blood vessel elements, CXCL8 and CXCL1 were absent in OND (D and E) and
normal (G and H) control tissue, despite the presence of GFAP-expressing astrocytes (F and I). Scale bars = 94 mm( A–C); 22.5 mm( D–I).
CXC receptors on human oligodendrocytes 1011
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 2000b; Salmaggi et al., 2002; Meeuwsen et al., 2003), we
extended our study to the in vitro level and demonstrated that
the proinﬂammatory cytokine IL-1b induced production by
astrocytes of signiﬁcantly higher amounts of CXCL8 and
CXCL1 than controls, while both IL-1b and IFN-g induced
high levels of CXCL10.
The latter observations further underscore the role played
by cytokines during the course of multiple sclerosis.
Microglia and inﬁltrating T lymphocytes are major
cytokine-producing cell types in the CNS, expressing both
IL-1b and IFN-g (Benvenuto et al., 1992; Link et al., 1994;
Cannella and Raine, 1995). Peak cytokine levels are detected
in active multiple sclerosis, with lower levels in silent cases,
and cytokines are generally absent in non-inﬂammatory OND
samples. This paradigm offers a possible mechanism under-
lying the observed CXC chemokine patterns in multiple
Fig. 5 Induced CXC chemokine production and secretion by astrocytes in vitro. Levels of CXCL8 (A and B), CXCL1 (C and D) and
CXCL10 (E and F) were detected by sandwich ELISA in supernatant ﬂuid collected from astrocyte cultures after 6–48 h treatment with
proinﬂammatory cytokines or LPS. IL-1b induced signiﬁcant release of CXCL8 and CXCL1 by human astrocytes in a time-dependent
manner, while IFN-g had no effect. In contrast, both IL-1b and IFN-g treatment resulted in induced CXCL10 production by astrocytes.
Limited amounts of CXCL8, CXCL1 and CXCL10 were detected in astrocyte supernatant ﬂuid following stimulation with LPS.
Concentration effects in A, C and E were tested in supernatant ﬂuid collected after 24 h incubation. Graph bars represent mean chemokine
secretion 6 SEM of astrocyte cultures from two different fetuses (n = 4). (
 )P < 0.03 compared with control untreated astrocytes.
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 sclerosis lesions. The presence of high levels of IL-1b and
IFN-g in early stages of the disease could lead to prominent
expression of CXCL8, CXCL1 and CXCL10, which sub-
sequently diminish as cytokine production wanes. Moreover,
the absence of proinﬂammatory cytokines in OND and nor-
mals might correspond to the observed lack of chemokines in
CNS samples from such cases. Therefore, CXC chemokine
receptors constitutively expressed on oligodendrocytes will
only be triggered by their speciﬁc ligands in active stages of
multiple sclerosis when cytokine, and consequently chemo-
kine, production is maximal.
Understanding of events leading to the accumulation or
recruitment of oligodendrocytes at the lesion margin might
be relevant to lesion repair. Such mechanisms could involve
molecules such as chemokines which are known to drive cell
migration and proliferation. In this regard, leading candidates
might be CXCR/CXCL pathways, whereby CXC receptor-
bearing oligodendrocytes might proliferate and accumulate at
the lesion margin in response to CXC ligand produced by
local astrocytes. Precedence for this might lie in studies in rats
where it has been shown that immature CXCR2-positive
oligodendrocytes proliferate in response to CXCL1 (from
astrocytes) in combination with PDGF-AA (Robinson et al.,
1998). Moreover, elevated levels of CXCL1 in the jimpy
mutant correlate with increased proliferation of NG2
+ oli-
godendrocyte progenitors (Wu et al., 2000). CXCL1 has also
been shown to provide a migratory stop signal for OPCs, thus
inﬂuencing positioning of cells of the oligodendrocyte lin-
eage during CNS development (Tsai et al., 2002). Although
no effect has been described on oligodendrocytes, CXCL8
and CXCL10 have been shown to induce proliferation of
other cell types, including endothelial cells and astrocytes
(Heidemann et al., 2003; Mockenhaupt et al., 2003; Zhu
et al., 2004).
Our ﬁnding that CXC chemokine receptors are consistently
present on human oligodendrocytes is in accord with the work
in rodents. In addition, the presence of the corresponding
ligands, CXCL8, CXCL1 and CXCL10, on hypertrophic
astrocytes (seen here primarily in active multiple sclerosis
lesions) suggests potential cross-talk with CXCR1, CXCR2
and CXCR3 on oligodendrocytes. Ongoing work is designed
to determine whether the chemokine/chemokine receptor
pairs, studied individually in vitro, are capable of inducing
human oligodendrocyte proliferation and downstream signal-
ling. On the other hand, it is equally possible that CXC
chemokines might be preventing oligodendrocyte migration
pastthelesionedge,andconsequentlydisruptrepairprocesses.
Togetherwithcytokineswhichdrivechemokineproduction,we
propose that interactions between CXC chemokines and their
receptors may play a key role in oligodendrocyte recruitment
around active multiple sclerosis lesions. Exploration of these
pathways may offer novel therapeutic avenues to enhance the
limited remyelination typically seen in multiple sclerosis.
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